Definium Therapeutics, Inc.
DFTX
Classement en actions
#3487
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Prix de l'action
$36.08
Capitalisation boursière
$4.85B
Changement (1 jour)
1.65%
Changement (1 an)
240.37%
Pays
US
Échange Definium Therapeutics, Inc. (DFTX)
Catégorie
Healthcare
Historique du prix de l'action pour Definium Therapeutics, Inc. (DFTX)
Prix de clôture le plus élevé : $10.57 le 2024-04-01
Prix de clôture le plus bas : $4.87 le 2020-03-01
Prix de clôture le plus bas : $4.87 le 2020-03-01
Historique du prix de l'action de Definium Therapeutics, Inc. de 2020 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
